Free Trial
NYSE:DGX

Quest Diagnostics (DGX) Stock Price, News & Analysis

$144.93
+0.82 (+0.57%)
(As of 10:15 AM ET)
Today's Range
$143.74
$145.55
50-Day Range
$135.64
$144.34
52-Week Range
$119.59
$145.62
Volume
54,761 shs
Average Volume
974,865 shs
Market Capitalization
$16.10 billion
P/E Ratio
19.51
Dividend Yield
2.07%
Price Target
$148.69

Quest Diagnostics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.31 Rating Score
Upside/​Downside
3.2% Upside
$148.69 Price Target
Short Interest
Healthy
2.05% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.68mentions of Quest Diagnostics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$246,400 Sold Last Quarter
Proj. Earnings Growth
7.39%
From $8.79 to $9.44 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.90 out of 5 stars

Medical Sector

23rd out of 912 stocks

Medical Laboratories Industry

2nd out of 18 stocks

DGX stock logo

About Quest Diagnostics Stock (NYSE:DGX)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

DGX Stock Price History

DGX Stock News Headlines

genetic testing test tube genome
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests (DGX)
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including
Quest Diagnostics: On A Quest For Growth
Biden backs new "game-changer for humanity" technology
Bill Gates is calling it America's most important project... and it's expected to impact half a million jobs and unlock $40 trillion in a rapidly growing industry.
Quest Diagnostics (NYSE:DGX) Raised to Buy at StockNews.com
Quest Diagnostics (NYSE:DGX) Upgraded to Buy by Citigroup
Biden backs new "game-changer for humanity" technology
Bill Gates is calling it America's most important project... and it's expected to impact half a million jobs and unlock $40 trillion in a rapidly growing industry.
See More Headlines
Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 4/22 Dividend
4/05/2024
Dividend Payable
4/22/2024
Last Earnings
4/23/2024
Ex-Dividend for 7/22 Dividend
7/08/2024
Today
7/15/2024
Dividend Payable
7/22/2024
Next Earnings (Confirmed)
7/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Health Care Services
CUSIP
74834L10
Employees
48,000
Year Founded
1967

Price Target and Rating

Average Stock Price Target
$148.69
High Stock Price Target
$165.00
Low Stock Price Target
$130.00
Potential Upside/Downside
+2.5%
Consensus Rating
Hold
Rating Score (0-4)
2.31
Research Coverage
13 Analysts

Profitability

Net Income
$854 million
Pretax Margin
12.05%

Debt

Sales & Book Value

Annual Sales
$9.25 billion
Cash Flow
$12.83 per share
Book Value
$56.41 per share

Miscellaneous

Free Float
110,214,000
Market Cap
$16.12 billion
Optionable
Optionable
Beta
0.89

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

DGX Stock Analysis - Frequently Asked Questions

How have DGX shares performed this year?

Quest Diagnostics' stock was trading at $137.88 at the beginning of the year. Since then, DGX shares have increased by 4.5% and is now trading at $144.11.
View the best growth stocks for 2024 here
.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) issued its quarterly earnings data on Tuesday, April, 23rd. The medical research company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.86 by $0.18. The business's quarterly revenue was up 1.7% on a year-over-year basis.
Read the conference call transcript
.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics' board approved a stock buyback program on Thursday, February 2nd 2023, which authorizes the company to repurchase $1,000,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 6% of its shares through open market purchases. Shares buyback programs are often an indication that the company's leadership believes its stock is undervalued.

What is Steve Rusckowski's approval rating as Quest Diagnostics' CEO?

1,053 employees have rated Quest Diagnostics Chief Executive Officer Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among the company's employees.

Does Quest Diagnostics have any subsidiaries?

Quest Diagnostics subsidiaries include these companies: MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and more.

Who are Quest Diagnostics' major shareholders?

Top institutional shareholders of Quest Diagnostics include SG Americas Securities LLC (0.11%), JGP Wealth Management LLC (0.09%), AMF Tjanstepension AB (0.08%) and QRG Capital Management Inc. (0.04%). Insiders that own company stock include Stephen H Rusckowski, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Timothy M Ring, Vicky B Gregg, Karthik Kuppusamy and Gail R Wilensky.
View institutional ownership trends
.

How do I buy shares of Quest Diagnostics?

Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE) and Abbott Laboratories (ABT).

This page (NYSE:DGX) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners